Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Go back to Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 80.01 +0.84 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $78.99 | 52 Week Low | $6.00 | |||
| Day High | $80.40 | P/E | N/A | |||
| Day Low | $78.27 | EPS | $-1.24 | |||
| Volume | 2,077,619 | |||||
